Holz_Marina_520Dr. Marina Holz, Doris and Dr. Ira Kukin Chair in Biology at Yeshiva University, recently delivered a keynote address at the Resveratrol 2017 Regional Meeting in Mendoza, Argentina, which met from October 12-October 13, 2017.

In her presentation, titled “Modulation of cellular signaling pathways by resveratrol,” she spoke about the recently funded clinical trial of resveratrol for treatment of Lymphangioleiomyomatosis (LAM), a rare lung disease. The trial looked at the safety and efficacy of a combined therapy using sirolimus and resveratrol as a potential remission-inducing treatment option for patients with LAM.

Sirolimus is a drug approved by the Food and Drug Administration that suppresses cell growth in LAM patients and is currently the first-line treatment option for most LAM patients. Resveratrol is a naturally occurring chemical found in the skin of grapes used to make red wine.

Tagged with:

Comments are closed.